Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)


 0.48 (6.28%)

Market Cap$86,340,301

12/13/17  3:59 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $8.12 with a 52 week high of $21.59 and a 52 week low of $7.20.

Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences


Read More

Gemphire Therapeutics Presents Data at American Heart Association (AHA) Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population and Reports Third Quarter 2017 Financial Results


Read More

Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting® 2017


Read More

There are currently no events scheduled.